Biotech investing is at a crossroads. Investors bemoan the FDA, citing endless delays and repeated requests for more information, adding time and cost to the drug development process. Many companies even head to Europe first to launch their drugs, hoping to achieve an exit without dealing with the FDA uncertainty. Despite these problems, biotech investing remains robust. In the latest Money Tree survey, biotech was still the #3 category in dollars invested. Does all this portend continued success for biotech or will the FDA problems lead to a funding reduction? Only our experts know for sure! Come hear our panel discuss these and other issues that are affecting the biotech landscape now and in the future.
Confirmed Speakers Include: Steve Bengston, PricewaterhouseCoopers Casper de Clercq, Norwest Venture Partners Jonathan MacQuitty, Abingworth Venture Capital Eric Shiozaki, Apposite Capital Moderator: Allison Tilley, Pillsbury Winthrop
Follow us at www.twitter.com/sdforum and tweet with us at #SDFBiotech
DISCLAIMER: Our aim is to continuously provide our
progressive audience with an open and interactive medium to view
and share relevant,
beneficial and interesting "career, economic, lifestyle and
networking" listings, ads, content and resources.
While the above information may be accurate and viable, the role
of Minority Professional Network, Inc. (MPN) is
strictly as a communications medium, and we do not
accept any responsibility for
cancellation, changes, errors, omissions, inconveniences, or any other form
of liability for any content
displayed or disseminated via our web sites, or e-marketing or social media
promotional services.
If there are any
doubts, we
encourage you to conduct additional research or contact the listed host or responsible entity.
CLICK HERE to inform us about any ads, listings or content
which appear to be
inappropriate,
fraudulent or misleading, or inconsistent with our theme and focus.